Dalhousie-Led Panel of 45 Recommends Screening for Eating Disorders Before Starting a GLP-1 Drug
In a three-round Delphi process published in World Psychiatry, 45 panelists, including specialists in diabetes, obesity, and eating disorders and people with lived experience, agreed that clinicians should screen for current and past eating disorders with a brief validated questionnaire before prescribing GLP-1 drugs and monitor symptoms during treatment. The panel says the drugs should generally be avoided in people with active anorexia nervosa, atypical anorexia nervosa, or bulimia with marked dietary restraint, and notes that evidence on GLP-1 drugs and eating disorders remains limited and inconsistent.